Sustained Quality of Life After Pancreatic Surgery for IPMNs in Young Patients: Long-Term Data and Clinical Implications

MedXY Editorial Team•Jul 11, 2026•Gastroenterology

Young patients (≤50 years) undergoing surgery for intraductal papillary mucinous neoplasms (IPMNs) report excellent long-term health-related quality of life (HRQoL), comparable to the age-matched general population.
Despite a considerable proportion requiring pancreatic enzyme replacement (63%) and insulin-dependent diabetes mellitus (16%), functional outcomes remain favorable post-resection.
Parenchyma-sparing pancreatic resections are associated with more favorable long-term quality of life outcomes compared to more extensive procedures.
Findings support early surgical intervention in young patients with IPMNs when clinically indicated, alleviating concerns about postoperative morbidity burden and long-term well-being.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Young patients (≤50 years) undergoing surgery for intraductal papillary mucinous neoplasms (IPMNs) report excellent long-term health-related quality of life (HRQoL), comparable to the age-matched general population.
Despite a considerable proportion requiring pancreatic enzyme replacement (63%) and insulin-dependent diabetes mellitus (16%), functional outcomes remain favorable post-resection.
Parenchyma-sparing pancreatic resections are associated with more favorable long-term quality of life outcomes compared to more extensive procedures.
Findings support early surgical intervention in young patients with IPMNs when clinically indicated, alleviating concerns about postoperative morbidity burden and long-term well-being.